Dose-related activity of stavudine in patients infected with human immunodeficiency virus

Eskild A. Petersen, Carlos H. Ramírez-Ronda, W. David Hardy, Robert Schwartz, Henry S. Sacks, Stephen Follansbee, Dolores M. Peterson, Anne Cross, Robert E. Anderson, Lisa M. Dunkle

Research output: Contribution to journalArticlepeer-review

59 Scopus citations

Abstract

In a multicenter, randomized, open-label, dose-ranging study to determine the relative effects of three dose levels of stavudine on CD4 lymphocyte count, weight gain, and hematologic variables in patients infected with human immunodeficiency virus (HIV), 152 patients with CD4 lymphocyte counts ≤600/mm3 received stavudine at 0.1 mg/kg/day (n = 51),0.5 rug/kg/day (n> = 53), or 2.0 rug/kg/day (n = 48). The study was designed to evaluate the activity of stavudine after 10 weeks of therapy and permitted extended dosing and follow-up for long-term safety. A significant dose effect on increases in CD4 lymphocyte counts and declines in HIV titer in peripheral blood mononuclear cells was observed. Stavudine was well-tolerated; the onlydose-related, dose-limiting adverse event was peripheral neuropathy, which usually was reversible. In this trial, the most favorable therapeutic index was seen at 0.5 rug/kg/day.

Original languageEnglish
Pages (from-to)S131-S139
JournalJournal of Infectious Diseases
Volume171
DOIs
StatePublished - Mar 1995

Fingerprint

Dive into the research topics of 'Dose-related activity of stavudine in patients infected with human immunodeficiency virus'. Together they form a unique fingerprint.

Cite this